Interaction Checker

Interacciones de Dupilumab

Dupilumab (Dupixent) tiene 23 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 0; moderadas: 23; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones moderadas (23)

  • Azelastina y fluticasonaantihistamínicoModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • BeclometasonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • BetametasonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • BudesonidacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • CiclesonidacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • ClobetasolcorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • DeflazacortcorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • DesonidacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • DexametasonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • FludrocortisonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • FluocinonidacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • FluticasonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • HalobetasolcorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • HidrocortisonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • MetilprednisolonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • MometasonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • PrednisolonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

  • TriamcinolonacorticosteroideModerada

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

Compruebe Dupilumab frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.